Trials / Completed
CompletedNCT02616250
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brimonidine 0.33% gel (Br) | |
| OTHER | CD07805/47 (Br) placebo gel | |
| DRUG | Ivermectin 1% cream (IVM) | |
| OTHER | CD5024 (IVM) placebo cream |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2015-11-26
- Last updated
- 2021-02-18
- Results posted
- 2017-10-19
Locations
13 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02616250. Inclusion in this directory is not an endorsement.